Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion type Assertion NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_head.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion description "[We are developing MHC class II (MHC II)-matched allogeneic, cell-based uveal melanoma vaccines that activate CD4(+) T lymphocytes, which are key cells for optimizing CD8(+) T-cell immunity, facilitating immune memory, and preventing tolerance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_provenance.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion evidence source_evidence_literature NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_provenance.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion SIO_000772 17483366 NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_provenance.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion wasDerivedFrom befree-20140225 NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_provenance.
- NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_assertion wasGeneratedBy ECO_0000203 NP733268.RABGZi2_pZYa4-E4jBdrLy0AXYSmCN2Q5-gOGoaBSbA9g130_provenance.